/Incyte%20Corp_%20logo%20and%20bar%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Valued at $14.5 billion by market cap, Incyte Corporation (INCY) is a biopharmaceutical company specializing in innovative treatments for hematology/oncology and autoimmune diseases. Based in Wilmington, Delaware, the company's portfolio includes notable treatments like Jakafi and Monjuvi, addressing a range of complex medical conditions.
Shares of this specialty drugmaker have underperformed the broader market over the past 52 weeks. INCY has risen marginally during this period, contrasting with the S&P 500 Index's ($SPX) robust rally of 28.1%. In 2024, INCY shares are up 2.5%, lagging behind SPX's 17.3% gain on a YTD basis.